A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors.

@inproceedings{Hashimoto2016API,
  title={A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors.},
  author={Kenji Hashimoto and Daniel Weiss and Yoshitaka Ogita and Mikiko Nakamura and Takahiro Ishiguro and Yuji Sano and Yoshiyuki Kinoshita and Mika Kamata Sakurai and Werner Frings and Shun-ichiro Komatsu and Akihisa Kaneko and Masamichi Ueda and Shohei Kishishita and Athos Gianella-Borradori},
  year={2016}
}
TPS2592Background: Despite recent advance of immunotherapy, not all patient benefit. Reasons for the limited therapeutic effect include a low level of target protein expression or tumor immunogenicity. Bispecific antibodies to engage T-cells onto tumor are one approach to more active immunotherapy. However, management of on target/off tumor adverse effects including cytokine release can be a challenge. Glypican 3 (GPC3) is expressed across variety of solid tumors including hepatocellular… CONTINUE READING

Similar Papers